Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BTU6
UPID:
P4K2A_HUMAN
Alternative names:
Phosphatidylinositol 4-kinase type II-alpha
Alternative UPACC:
Q9BTU6; D3DR59; Q9NSG8
Background:
Phosphatidylinositol 4-kinase type 2-alpha, also known as Phosphatidylinositol 4-kinase type II-alpha, plays a pivotal role in cellular processes by catalyzing the phosphorylation of phosphatidylinositol to phosphatidylinositol 4-phosphate. This reaction is crucial for endocytosis, Golgi function, protein sorting, and membrane trafficking, and supports prolonged survival of neurons.
Therapeutic significance:
Understanding the role of Phosphatidylinositol 4-kinase type 2-alpha could open doors to potential therapeutic strategies.